Tirzepatide peptide 15mg: reaching the top of the Mounjaro schedule

Step 1: the schedule that leads to 15mg

Tirzepatide's licensed UK titration runs in six four-weekly steps: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and then 15mg. The early doses are there to let your body adjust, nausea and other gut symptoms are most likely when the medicine is new to your system, and slower increases reduce them. Your prescriber decides the pace; some people hold at an intermediate dose longer if side effects are still noticeable.

A common misconception worth clearing up gently: people sometimes assume 15mg is the "real" dose and the earlier ones are just placebo-adjacent warmup. That is not quite right. Every step on the schedule is clinically active. Even at 5mg, many patients see meaningful changes in appetite and weight. The higher doses tend to produce greater effects on average, but the individual picture varies, which is exactly why a prescriber reviews you at each stage rather than simply bumping everyone to the top.

Detailed guidance on the full titration sequence, including what to expect at each step, is set out in the tirzepatide dosing guide on this site. For now, the relevant point about 15mg is that it arrives at the end of a process, not at the beginning of one.

Step 2: what the evidence says at 15mg

The SURMOUNT-1 trial (which enrolled 2,539 adults with obesity and no diabetes, running over 72 weeks) is the primary evidence base for tirzepatide in weight management. Participants on 15mg achieved an average weight reduction of around 20–21%, with some analyses reporting up to approximately 22.5%. Those are the figures NICE cited when recommending tirzepatide in TA1026, published in December 2024. You can read the NICE appraisal of tirzepatide directly for the committee's assessment of that data.

For context, the 10mg dose produced average losses of around 19.5% in the same trial. The gap between 10mg and 15mg is real but narrower than the gap between, say, 2.5mg and 10mg. That pattern matters clinically: for some patients, 10mg may represent the optimum balance of efficacy and tolerability, and the prescriber's job is to find that point for each individual. You can look at how tirzepatide 10mg sits in the sequence if you want to understand how the steps compare.

The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found that tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity, useful context when considering how 15mg sits relative to other licensed options. For those researching higher-concentration research-use peptides that sit outside the licensed titration, our page on 30 mg tirzepatide peptide covers what that product is and how it differs from the doses used in clinical practice.

Step 3: prescriber review before every dose increase

At nume, no dose increase happens automatically. Before each step up (including the move to 15mg) our prescribers review your weight, progress and how you have tolerated the previous dose. That review involves real evidence: weight records, any side effects you have reported, and whether you are still losing at a rate that justifies the increase. A clinical team with prescribing responsibility sits behind every decision.

This matters particularly at the higher doses. The NHS tirzepatide guidance, alongside the licensed SmPC, makes clear that continuing treatment should be reassessed if less than 5% body weight has been lost after six months at the highest tolerated dose. That is a clinical checkpoint, not a punishment. If 12.5mg has produced solid results and 15mg adds little for a particular patient, there is no clinical case to push further.

The broader picture of how Mounjaro works as a medicine (its dual GIP and GLP-1 mechanism, its licensed indications, and how it compares with other options) is covered on the main Mounjaro overview page. If you are thinking about starting treatment rather than advancing through it, the weight-loss treatment overview is the better starting point.

Side effects at 15mg: broadly consistent, worth knowing

The side-effect profile at 15mg is the same class as lower doses, gastrointestinal effects lead: nausea, diarrhoea, constipation, reflux, indigestion. These are most common after a dose increase and typically settle within days to a couple of weeks as the body adjusts. The NHS medicines information for tirzepatide on the NHS website lists the full side-effect profile with guidance on when to seek help.

One thing to be aware of at any dose, including 15mg: severe and persistent stomach pain that radiates to the back should prompt urgent medical attention, as this can be a sign of acute pancreatitis, a known but uncommon risk with GLP-1 class medicines. Report any suspected side effects using the MHRA Yellow Card scheme.

For people considering what comes after a dose plateau, or curious about compounded alternatives they may have seen advertised, our page on getting Mounjaro safely through a regulated UK pharmacy explains how the licensed supply chain works. If you are already on treatment and want to understand the cost side of things, current treatment pricing and what it includes is available on the treatment page. When you are ready to speak to a prescriber about your own situation, that is also the place to start your free consultation.